MA40094B1 - Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation - Google Patents
Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisationInfo
- Publication number
- MA40094B1 MA40094B1 MA40094A MA40094A MA40094B1 MA 40094 B1 MA40094 B1 MA 40094B1 MA 40094 A MA40094 A MA 40094A MA 40094 A MA40094 A MA 40094A MA 40094 B1 MA40094 B1 MA 40094B1
- Authority
- MA
- Morocco
- Prior art keywords
- interleukin
- polypeptide
- methods
- fusion proteins
- fusion protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
Abstract
L'invention concerne divers procédés et compositions qui peuvent être employés pour moduler le système immunitaire. Les compositions comprennent une protéine de fusion comprenant : a) un premier polypeptide comprenant l'interleukine-2 (il-2) ou un variant ou fragment fonctionnel de celle-ci; et b) un second polypeptide, fusionné dans le cadre au premier polypeptide, dans lequel le second polypeptide comprend un domaine extracellulaire du récepteur alpha de l'interleukine-2 (il-2 ra) ou un variant ou fragment fonctionnel de celui-ci, et où la protéine de fusion présente une activité d'il-2. Divers procédés sont proposés pour moduler la réponse immunitaire chez un sujet comprenant l'administration à un sujet qui en a besoin d'une quantité thérapeutiquement efficace de la protéine de fusion d'il-2/il-2ra selon l'invention.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462033726P | 2014-08-06 | 2014-08-06 | |
PCT/US2015/043792 WO2016022671A1 (fr) | 2014-08-06 | 2015-08-05 | Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation |
Publications (2)
Publication Number | Publication Date |
---|---|
MA40094A1 MA40094A1 (fr) | 2021-09-30 |
MA40094B1 true MA40094B1 (fr) | 2022-05-31 |
Family
ID=53836871
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA040721A MA40721A (fr) | 2014-08-06 | 2015-08-04 | Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation |
MA40094A MA40094B1 (fr) | 2014-08-06 | 2015-08-04 | Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA040721A MA40721A (fr) | 2014-08-06 | 2015-08-04 | Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation |
Country Status (22)
Country | Link |
---|---|
US (2) | US20170233448A1 (fr) |
EP (1) | EP3177307A1 (fr) |
JP (3) | JP6723982B2 (fr) |
KR (1) | KR102653758B1 (fr) |
CN (2) | CN107074967B (fr) |
AU (3) | AU2015301071C1 (fr) |
BR (1) | BR112017001940A2 (fr) |
CA (1) | CA2957273C (fr) |
CL (1) | CL2017000284A1 (fr) |
CO (1) | CO2017002166A2 (fr) |
EA (2) | EA202091342A3 (fr) |
IL (2) | IL250007B (fr) |
MA (2) | MA40721A (fr) |
MX (1) | MX2017001062A (fr) |
MY (1) | MY180831A (fr) |
PE (1) | PE20170503A1 (fr) |
PH (1) | PH12017500042A1 (fr) |
SA (1) | SA517380842B1 (fr) |
SG (2) | SG11201700706WA (fr) |
TN (1) | TN2017000020A1 (fr) |
WO (1) | WO2016022671A1 (fr) |
ZA (1) | ZA201700245B (fr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
CA2931114A1 (fr) | 2014-02-06 | 2015-08-13 | F. Hoffmann-La Roche Ag | Proteines hybrides de l'interleukine-2 et leurs utilisations |
MA40721A (fr) * | 2014-08-06 | 2017-06-13 | The Univ Of Miami | Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation |
EP3458485B1 (fr) * | 2016-05-19 | 2021-12-29 | The General Hospital Corporation | Interleukine-2 liée à son récepteur il-2rbêta, plate-forme pour améliorer l'activité des cellules tueuses naturelles et des lymphocytes t régulateurs |
AU2017335771A1 (en) | 2016-09-28 | 2019-02-28 | Musc Foundation For Research Development | Antibodies that bind interleukin-2 and uses thereof |
EP3596108A4 (fr) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | Immunotolérance ciblée |
JP2020521452A (ja) | 2017-05-24 | 2020-07-27 | パンディオン・セラピューティクス・インコーポレイテッド | 標的化免疫寛容 |
CA3084262A1 (fr) | 2017-12-06 | 2019-06-13 | The Board Of Trustees Of The Leland Stanford Junior University | Proteines modifiees pour ameliorer la sensibilite d'une cellule a l'il-2 |
US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
EP3768700A1 (fr) * | 2018-03-23 | 2021-01-27 | Kite Pharma, Inc. | Protéines transmembranaires chimériques et leurs utilisations |
AR115024A1 (es) | 2018-03-28 | 2020-11-18 | Bristol Myers Squibb Co | PROTEÍNAS DE FUSIÓN INTERLEUCINA-2 / RECEPTOR a DE INTERLEUCINA-2 Y MÉTODOS DE USO |
EP3941935A1 (fr) * | 2019-03-18 | 2022-01-26 | Biontech Cell & Gene Therapies Gmbh | Variants du récepteur de l'interleukine-2 (il2r) et de l'interleukine-2 (il2) pour l'activation spécifique de cellules effectrices immunitaires |
CN111944036A (zh) | 2019-05-14 | 2020-11-17 | 上海盖浦生物科技有限公司 | 一种增殖免疫细胞的突变体蛋白 |
JP2022533702A (ja) | 2019-05-20 | 2022-07-25 | パンディオン・オペレーションズ・インコーポレイテッド | MAdCAM標的化免疫寛容 |
US20220227837A1 (en) * | 2019-05-24 | 2022-07-21 | Proviva Therapeutics (Hong Kong) Limited | Il-2 compositions and methods of use thereof |
US11246906B2 (en) * | 2019-06-11 | 2022-02-15 | Alkermes Pharma Ireland Limited | Compositions and methods for subcutaneous administration of cancer immunotherapy |
US20220378933A1 (en) * | 2019-09-19 | 2022-12-01 | Proviva Therapeutics (Hong Kong) Limited | Il-2 compositions and methods of use thereof |
EP4045077A1 (fr) * | 2019-10-18 | 2022-08-24 | Alkermes Pharma Ireland Limited | Agents il-2 immunolodulateurs en combinaison avec des inhibiteurs de point de contrôle immunitaire |
AU2020407233A1 (en) | 2019-12-20 | 2022-08-18 | Regeneron Pharmaceuticals, Inc. | Novel IL2 agonists and methods of use thereof |
US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
CN115996946A (zh) | 2020-04-30 | 2023-04-21 | 免疫靶向有限公司 | 可活化il2组合物和使用方法 |
WO2023154894A2 (fr) * | 2022-02-11 | 2023-08-17 | Alkermes Pharma Ireland Limited | Compositions et procédés d'immunothérapie anticancéreuse |
WO2023159135A2 (fr) * | 2022-02-16 | 2023-08-24 | University Of Miami | Protéines de fusion il-2 et tl1a et leurs procédés d'utilisation |
CN114875069B (zh) * | 2022-04-22 | 2023-09-15 | 四川大学 | 基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1298144A3 (fr) * | 1994-12-28 | 2006-05-31 | University of Kentucky Research Foundation | Anticorps monoclonal anti-idiotype murin 3H1 |
DE19701141C1 (de) * | 1997-01-16 | 1998-04-09 | Hoechst Ag | Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen |
EP1447451A4 (fr) * | 2001-09-28 | 2006-06-07 | Dnavec Research Inc | Vecteur viral infectant une cellule de mammifere, codant pour la beta2m liee a un epitope |
MX2007014474A (es) * | 2005-05-17 | 2008-02-07 | Univ Connecticut | Composiciones y metodos para inmunomodulacion en un organismo. |
CN101255197B (zh) * | 2008-03-28 | 2012-01-25 | 浙江海正药业股份有限公司 | 血清白蛋白与白介素1受体拮抗剂的融合蛋白及应用 |
GB0815216D0 (en) * | 2008-08-21 | 2008-09-24 | Asterion Ltd | Interleukin |
WO2011123683A2 (fr) * | 2010-04-02 | 2011-10-06 | University Of Rochester | Cytokines activées par des protéases |
US20140044675A1 (en) * | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
MA40721A (fr) | 2014-08-06 | 2017-06-13 | The Univ Of Miami | Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation |
-
2015
- 2015-08-04 MA MA040721A patent/MA40721A/fr unknown
- 2015-08-04 MA MA40094A patent/MA40094B1/fr unknown
- 2015-08-05 KR KR1020177005686A patent/KR102653758B1/ko active IP Right Grant
- 2015-08-05 CN CN201580042330.XA patent/CN107074967B/zh active Active
- 2015-08-05 BR BR112017001940A patent/BR112017001940A2/pt active Search and Examination
- 2015-08-05 WO PCT/US2015/043792 patent/WO2016022671A1/fr active Application Filing
- 2015-08-05 SG SG11201700706WA patent/SG11201700706WA/en unknown
- 2015-08-05 MY MYPI2017700387A patent/MY180831A/en unknown
- 2015-08-05 US US15/501,392 patent/US20170233448A1/en active Pending
- 2015-08-05 PE PE2017000128A patent/PE20170503A1/es unknown
- 2015-08-05 EA EA202091342A patent/EA202091342A3/ru unknown
- 2015-08-05 JP JP2017506395A patent/JP6723982B2/ja active Active
- 2015-08-05 EA EA201790063A patent/EA035956B1/ru not_active IP Right Cessation
- 2015-08-05 MX MX2017001062A patent/MX2017001062A/es unknown
- 2015-08-05 SG SG10201913695PA patent/SG10201913695PA/en unknown
- 2015-08-05 TN TN2017000020A patent/TN2017000020A1/en unknown
- 2015-08-05 CA CA2957273A patent/CA2957273C/fr active Active
- 2015-08-05 EP EP15750560.3A patent/EP3177307A1/fr active Pending
- 2015-08-05 AU AU2015301071A patent/AU2015301071C1/en active Active
- 2015-08-05 CN CN202110539190.4A patent/CN113912737A/zh active Pending
-
2017
- 2017-01-06 PH PH12017500042A patent/PH12017500042A1/en unknown
- 2017-01-09 IL IL250007A patent/IL250007B/en active IP Right Grant
- 2017-01-11 ZA ZA2017/00245A patent/ZA201700245B/en unknown
- 2017-02-03 CL CL2017000284A patent/CL2017000284A1/es unknown
- 2017-02-05 SA SA517380842A patent/SA517380842B1/ar unknown
- 2017-03-03 CO CONC2017/0002166A patent/CO2017002166A2/es unknown
-
2020
- 2020-05-22 AU AU2020203352A patent/AU2020203352B2/en active Active
- 2020-06-24 JP JP2020108721A patent/JP7272663B2/ja active Active
- 2020-07-09 IL IL275944A patent/IL275944B/en unknown
-
2022
- 2022-06-10 AU AU2022204034A patent/AU2022204034A1/en not_active Abandoned
- 2022-08-25 US US17/822,333 patent/US20230079120A1/en active Pending
-
2023
- 2023-04-20 JP JP2023069282A patent/JP2023099045A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA40094B1 (fr) | Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation | |
CY1123783T1 (el) | Antiσωμαta enanti-b7-h3 και συζευγματα αντισωματος φαρμακου | |
MX2021008144A (es) | Composiciones para aumentar la media vida de un agente terapeutico en caninos y metodos de uso. | |
MX2020010910A (es) | Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos. | |
MA40041B1 (fr) | Anticorps anti-gitr et leurs procédés d'utilisation | |
EA201891656A1 (ru) | Молекулы, которые избирательно активируют регуляторные t-клетки для лечения аутоиммунных заболеваний | |
MX2019001651A (es) | Citocina fusionada a fc heterodimerico, y composicion farmaceutica que comprende la misma. | |
MA39313A1 (fr) | Anticorps anti-egfrviii et leurs utilisations dans le traitement de divers cancers | |
MA43458A1 (fr) | Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers | |
AU2015269210A8 (en) | Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof | |
MA40801A1 (fr) | Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123 | |
MX2021005018A (es) | Composicion farmaceutica de proteina de fusion del receptor tgf-?, y uso de la misma. | |
MX2021010531A (es) | Proteina de fusion bifuncional y uso farmaceutico de la misma. | |
WO2016014428A3 (fr) | Molécules qui activent sélectivement les cellules t régulatrices pour le traitement de maladies auto-immunes | |
MX2018015285A (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. | |
MA43817B1 (fr) | Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2 | |
Snell et al. | IL-15–Dependent Upregulation of GITR on CD8 Memory Phenotype T Cells in the Bone Marrow Relative to Spleen and Lymph Node Suggests the Bone Marrow as a Site of Superior Bioavailability of IL-15 | |
MA43767B1 (fr) | Anticorps non antagonistes dirigés contre la chaine alpha du domaine extracellulaire du récepteur de l'il-7 et leur utilisation dans le traitement du cancer | |
MA43113A (fr) | Anticorps anti-htr a1 et méthodes d'utilisation de ceux-ci | |
WO2020136145A3 (fr) | Anticorps neutralisant le récepteur de type immunoglobuline des leucocytes | |
MX2021002208A (es) | Regimenes de dosificacion de la proteina de fusion de fc y dominio extracelular del cd80. | |
EA202091239A1 (ru) | Слитый белок на основе терапевтического фермента, имеющий новую структуру, и его применение | |
SG11202000115SA (en) | Novel therapeutic enzyme fusion protein and use thereof | |
WO2018175740A8 (fr) | Anticorps anti-tmeff1 et conjugués anticorps-médicament | |
MA48751B1 (fr) | Paradigme de traitement d'anticorps anti-cd19 et traitement de combinaison venetoclax |